



Oncology bulletin

June 2025

The aim of this current awareness bulletin is to provide a digest of recent guidelines, reports, research and best practice on Oncology

If you would like to request any of the articles included in this bulletin, or be put onto the distribution list, please contact: ulth.library.grantham@nhs.net

For more information on Library and Knowledge Services please go to:
www.nhslincslibrary.uk

Cancer Treatments

Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade

Local anesthetics promote anticancer immune responses.

Liwei Zhao et al

Journal for ImmunoTherapy of Cancer 13 e010714 (open access)

Diagnosis

Mismatch in testing: a retrospective analysis of mismatch repair testing in endometrial cancer and Lynch syndrome diagnosis in multiple specialist centres in the UK and Ireland (March 2022– March 2023)

Neil Ryan et al

BMJ Oncology 4 e000688 (open access)

Bridging the gap between guidelines and practice in Lynch syndrome screening for endometrial cancer

Hiroshi Yoshida

BMJ Oncology 4 e000821 (open access)

Cancer in people with intellectual disability: lower incidence, later-stage diagnosis – who counts? who cares?

Editorial (see article below)

Martin McMahon et al

BMJ Oncology 4 e000845 (open access)

Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study

Maarten Cuypers et al



BMJ Oncology 4 e000686 (open access)

General

Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations

Immune checkpoint inhibitors (ICIs) have an expanding role in the management of numerous cancers. Hyperglycaemia is commonly seen in patients treated with ICIs. However, the differential diagnosis for hyperglycaemia is broad, and incorrect diagnosis can have serious consequences.

Linda Wu et al

Journal for ImmunoTherapy of Cancer 13 e011271 (open access)

Symptoms, side effects, quality of life and financial toxicity matter to patients with cancer, we need to do a better job of capturing and reporting these concepts in trials and clinical care

Editorial (for article below)

Melanie Calvert et al

BMJ Oncology 4 e000879 (open access)

Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)

Alberto Puccini et al

BMJ Oncology 4 e000783 (open access)

Specific Cancers

Are there inequalities in ovarian cancer diagnosis and treatment in England? A population-based study

This study examines disparities in treatment received and the timeliness of diagnosis and treatment across different socioeconomic groups in England, a country with universal healthcare.

Benjamin A. Pickwell-Smith et al

Cancer Epidemiology 96 102778

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance

NICE ta1064



Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance

NICE ta1065

EGFR-mutated non-small cell lung cancer

Sacituzumab tirumotecan shows promise (Editorial)

Xiaoxiao Ma et al

BMJ 389 r1154

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Wenfeng Fang et al

BMJ 389 e085680 (open access)

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data

Adjuvant trastuzumab in combination with chemotherapy has significantly improved survival in patients with HER2-positive early breast cancer but, since introduction in 2005, the 12 months duration has been questioned and trials have tested shorter durations.

Helena M Earl et al

BMJ Oncology 4 e000810 (open access)